Search Results for: First+in+Human
RB nr 27 Informacja nt. wyboru wykonawcy w celu zorganizowania i kompleksowego przeprowadzenia badania klinicznego pierwszej fazy typu ‘First in Human’ dla związku OATD-02
Read moreFirst patient in the UK is dosed in the OATD-01 Phase 2 KITE study in pulmonary sarcoidosis
- OATD-01 is an innovative, first-in-class chitinase inhibitor for the treatment of sarcoidosis among other diseases where chronic inflammation leads to tissue remodeling and fibrosis - In the phase II clinical trial (KITE study), patients will
Read moreMolecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
OATD-02 is an oral, potent and selective dual arginase inhibitor (ARG1 and ARG2) for the treatment of cancer Phase I clinical trial to assess safety, tolerability and preliminary efficacy of OATD-02 in patients with advanced and/or
Read moreMolecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
Initiation of Phase II clinical trial of OATD-01 (KITE) for the treatment of pulmonary sarcoidosis following approval from the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). World's
Read moreThe U.S. Food and Drug Administration Gives the Green Light to Molecure’s Flagship Program – Phase II Clinical Testing of OATD-01 is Ready for Launch
Molecure can proceed with clinical trials in the U.S.A – Phase II proof-of-concept study will be the first to treat patients suffering from pulmonary sarcoidosis with OATD-01 In the coming weeks Molecure will also seek the
Read moreMolecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule OATD-01, taking another important step in the development of this program.
The agreement with Simbec-Orion includes organizing and fully executing a proof-of-concept Phase II clinical trial in patients with pulmonary sarcoidosis. The Phase II proof-of-concept study of OATD-01 will be conducted as multi-center and international clinical trial
Read moreOncoArendi Therapeutics Reports Continued Strategic and Operational Momentum for 12 Months ended 31 December 2021
- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi’s small molecule RNA platform - Novel dual acting first-in-class arginase inhibitor OATD-02
Read moreOncoArendi Therapeutics Appoints Dr. Adam Gołębiowski, Dr. Zbigniew Zasłona and Agnieszka Rajczuk-Szczepańska to its Management Board
New members to bring additional scientific, operational and HR expertise Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to
Read more